Related Experiment Videos
Metabolic considerations in hypertension
1Department of Medicine, Los Angeles School of Medicine, University of California.
Insights
Hypertension, obesity, and diabetes share common metabolic and genetic factors. Calcium channel blockers and ACE inhibitors are recommended first-line treatments for obese and diabetic hypertensive patients.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Hypertension Research
Background:
- Hypertension frequently co-occurs with obesity and diabetes mellitus, indicating shared underlying genetic and environmental factors.
- These conditions contribute to metabolic and cardiovascular derangements, accelerating atherosclerosis and increasing morbidity and mortality.
- Abnormalities in blood pressure regulation, including the renin-angiotensin system and sympathetic nervous system, are observed in diabetes.
Purpose of the Study:
- To explore the interconnectedness of hypertension, obesity, and diabetes mellitus.
- To identify common metabolic and vascular characteristics linking these conditions.
- To guide optimal pharmacotherapy selection for hypertensive individuals with obesity and diabetes.
Main Methods:
- Review of existing literature on the pathophysiology of hypertension, obesity, and diabetes.
- Analysis of metabolic and vascular adaptations associated with these conditions.
- Evaluation of medication classes for efficacy and metabolic impact in this patient population.
Main Results:
- Insulin resistance is proposed as a unifying link between hypertension, obesity, and diabetes.
- Early signs of sodium retention and cardiovascular hyperreactivity in diabetes may precede hypertension.
- Obesity is associated with altered sympathetic activity, sodium metabolism, and hemodynamics, predisposing to hypertension.
Conclusions:
- Calcium channel blockers and angiotensin-converting enzyme inhibitors are effective first-line treatments for obese and diabetic hypertensives due to their favorable metabolic profiles.
- Diuretics and beta-blockers may not be ideal initial choices due to potential metabolic complications in this patient group.
- Understanding the metabolic interplay is crucial for selecting medications that avoid adverse effects in patients with co-existing hypertension, obesity, and diabetes.
Abstract:
The frequent concurrence of other cardiovascular risk factors in hypertensive patients, such as obesity and diabetes mellitus, suggests that overlapping genetic and environmental factors may contribute to the common metabolic and cardiovascular derangements observed in these populations. Hypertension and hyperglycemia accelerate atherosclerosis in diabetics, and play an important role in associated morbidity and mortality. Several abnormalities in blood pressure regulatory systems such as the renin-angiotensin system, the sympathetic nervous system, and sodium/volume control have been described in diabetes mellitus. Sodium retention and cardiovascular hyperreactivity appear to occur early in the course of diabetes mellitus, even at normal blood pressure levels and before onset of renal failure, and could set the stage for the development of hypertension. The relationship between obesity and hypertension is also well-established, and may reflect metabolic and cardiovascular adaptations in obese subjects which predispose to blood pressure elevations. Obese subjects display changes in sympathetic nervous system activity, sodium metabolism, and vascular hemodynamics. Sodium-sensitive blood pressure responses in the obese may be secondary to increased cardiac output or fluid volume, and are directly related to circulating insulin levels. Certain metabolic and vascular characteristics of obesity and diabetes mellitus are found in patients with essential hypertension. It has been suggested that insulin and insulin resistance may be the common link between these risk factors. Improved understanding of metabolic considerations in the treatment of obese and diabetic hypertensives should lead to more careful selection of medications that avoid metabolic complications. Although diuretics and beta-blockers may be useful in some patients, there are several reasons not to recommend their use as initial therapy in obese and diabetic hypertensives. On the other hand, calcium channel blockers and angiotensin converting enzyme inhibitors are highly effective, with minimal effects on metabolic parameters, and are well-suited as first-line therapy in the treatment of obese and diabetic hypertensives.